And yet another blow for an Ionis CNS antisense drug candidate….
Following the announcement last October of Phase 3 failure of tofersen in adults with ALS associated with a SOD1 mutation, Biogen and Ionis have suffered another disappointment in the ALS pipeline after BIIB078 (IONIS-C9Rx) failed to demonstrate clinical benefit in a 106 patient Phase 1 trial. BIIB078 is an investigational antisense therapy for the treatment of C9orf72-associated ALS.
No consistent difference was seen between the 60mg cohort and placebo and the 90mg cohort showed a greater decline on secondary endpoints than placebo.
https://www.prnewswire.com/news-rel...-amyotrophic-lateral-sclerosis-301511359.html
https://www.fiercebiotech.com/biote...t-quits-als-med-after-it-flunks-phase-1-trial
https://pharmaphorum.com/news/new-b...ogen-and-ionis-candidate-fails-phase-1-trial/
- Forums
- ASX - By Stock
- Ann: Retina Target Engagement Confirmed in Large Eye
And yet another blow for an Ionis CNS antisense drug candidate…....
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
12.0¢ |
Change
0.010(9.09%) |
Mkt cap ! $559.9M |
Open | High | Low | Value | Volume |
11.0¢ | 12.5¢ | 11.0¢ | $333.8K | 2.839M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 252532 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 628395 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 252532 | 0.120 |
1 | 260869 | 0.115 |
1 | 9090 | 0.110 |
4 | 339800 | 0.105 |
9 | 659229 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 628395 | 8 |
0.130 | 823337 | 12 |
0.135 | 1051848 | 8 |
0.140 | 453116 | 2 |
0.145 | 56265 | 2 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online